Minocycline as Treatment for Psychiatric and Neurological Conditions: A Systematic Review and Meta-Analysis.

Bianca E Kavanagh, Olivia M Dean, Michael Berk, Ken Walder, Lesley Berk, Laura Gray, Alyna Turner, Mohammadreza Mohebbi, Margaret J Morris, Bruna Panizzutti, Kyoko Hasebe, Adam J Walker, Wolfgang Marx, Chiara Cristina Bortolasci, Alcy Meehan, Sarah Croce, Sylvia Lin, David Skvarc

Journal: International journal of molecular sciences 2023;24(6):5250

PMID: 36982324

Abstract

["Minocycline has anti-inflammatory, antioxidant, and anti-apoptotic properties that explain the renewed interest in its use as an adjunctive treatment for psychiatric and neurological conditions. Following the completion of several new clinical trials using minocycline, we proposed an up-to-date systematic review and meta-analysis of the data available. The PICO (patient\/population, intervention, comparison and outcomes) framework was used to search 5 databases aiming to identify randomized controlled trials that used minocycline as an adjunctive treatment for psychiatric and neurological conditions. Search results, data extraction, and risk of bias were performed by two independent authors for each publication. Quantitative meta-analysis was performed using RevMan software. Literature search and review resulted in 32 studies being included in this review: 10 in schizophrenia, 3 studies in depression, and 7 in stroke, with the benefit of minocycline being used in some of the core symptoms evaluated; 2 in bipolar disorder and 2 in substance use, without demonstrating a benefit for using minocycline; 1 in obsessive-compulsive disorder, 2 in brain and spinal injuries, 2 in amyotrophic lateral sclerosis, 1 in Alzheimer's disease, 1 in multiple systems atrophy, and 1 in pain, with mixes results. For most of the conditions included in this review the data is still limited and difficult to interpret, warranting more well-designed and powered studies. On the other hand, the studies available for schizophrenia seem to suggest an overall benefit favoring the use of minocycline as an adjunctive treatment."]
Address: IMPACT, Institute for Innovation in Physical and Mental Health and Clinical Translation, Barwon Health, School of Medicine, Deakin University, Geelong, VIC 3220, Australia.; School of Psychology, Faculty of Health, Deakin University, Geelong, VIC 3220, Australia.; Melbourne Neuropsychiatry Centre, University of Melbourne, Parkville, VIC 3053, Australia.; School of Biomedical Sciences, UNSW Sydney, Kensington, NSW 2052, Australia.; Biostatistics Unit, Faculty of Health, Deakin University, Burwood, VIC 3125, Australia.; Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3052, Australia.; Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC 3052, Australia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.